We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.07%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$705M
AUM Growth
+$41.3M
Cap. Flow
+$7.11M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.32%
Holding
99
New
15
Increased
51
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$24.2M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$16.8M
3
CLSD
Clearside Biomedical
CLSD
+$13.9M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$8.94M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$8.79M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$23.9M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.6M
3
CELG
Celgene Corp
CELG
+$10M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$9.47M
5
RMTI icon
Rockwell Medical
RMTI
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVCT.WS
76
DELISTED
PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
$414K 0.06%
2,200,000
– –
IVTY
77
DELISTED
Invuity, Inc
IVTY
$326K 0.05%
+34,200
New +$238K
AGTC
78
DELISTED
Applied Genetic Technologies Corporation
AGTC
$245K 0.03%
17,321
+211
+1% +$3.29K
ADAP
79
DELISTED
Adaptimmune Therapeutics
ADAP
$206K 0.03%
25,307
+307
+1% +$2.89K
ONSIW
80
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$192K 0.03%
+416,666
New +$160K
ONSIZ
81
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$187K 0.03%
+416,666
New +$219K
CLRB icon
82
Cellectar Biosciences
CLRB
$20.2M
$185K 0.03%
18
– –
CLRBW
83
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$29K ﹤0.01%
+52,999
New +$32.3K
ALKS icon
84
Alkermes
ALKS
$8.39B
– –
-700,000
Closed -$23.9M
BCRX icon
85
BioCryst Pharmaceuticals
BCRX
$2.35B
– –
-1,080,000
Closed -$3.06M
RGLS
86
DELISTED
Regulus Therapeutics
RGLS
– –
-255
Closed -$212K
RMTI icon
87
Rockwell Medical
RMTI
$28M
– –
-10,045
Closed -$8.3M
TPST icon
88
Tempest Therapeutics
TPST
$13.8M
– –
-86
Closed -$2.39M
VCYT icon
89
Veracyte
VCYT
$4.77B
– –
-137,990
Closed -$745K
MRTX
90
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-495,356
Closed -$10.6M
BLCM
91
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-30,000
Closed -$2.81M
SRRA
92
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-1,329
Closed -$358K
KITE
93
DELISTED
Kite Pharma, Inc.
KITE
– –
-68,800
Closed -$3.16M
CPXX
94
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-620,000
Closed -$6.84M
BITI
95
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
– –
-50,000
Closed -$1.32M
CELG
96
DELISTED
Celgene Corp
CELG
– –
-100,000
Closed -$10M
EPRS
97
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
– –
-896,600
Closed -$2.41M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Cormorant Asset Management held 99 positions worth $705M, up 6.2% from $664M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cormorant Asset Management's Q2 2016 filing shows 15 new, 51 increased, 12 reduced and 16 closed positions. Its largest new stake was Theravance Biopharma: 1,118,372 shares worth $25.4M. The largest sale was Alkermes, an estimated $23.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier.

  • Cormorant Asset Management's largest Q2 2016 buy was Theravance Biopharma: 1,118,372 shares worth $25.4M.
  • Cormorant Asset Management added most to Minerva Neurosciences in Q2 2016, an estimated $8.32M increase.
  • Cormorant Asset Management's biggest Q2 2016 reduction was Neurocrine Biosciences, cutting an estimated $9.47M.
  • Cormorant Asset Management fully exited Alkermes in Q2 2016, selling an estimated $23.9M.
  • Cormorant Asset Management's ten largest holdings make up 40% of its $705M portfolio in Q2 2016.
  • Cormorant Asset Management opened 15 new positions and closed 16 in Q2 2016.
  • Cormorant Asset Management's portfolio value rose 6.2% quarter-over-quarter to $705M.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.